Assessing the value of a new pharmaceutical
| dc.contributor.author | O'Brien, Bernie J. | en_US |
| dc.contributor.author | Centre for Health Economics and Policy Analysis | en_US |
| dc.date.accessioned | 2015-04-14T14:41:53Z | |
| dc.date.available | 2015-04-14T14:41:53Z | |
| dc.date.issued | 1996 | en_US |
| dc.description | Bernie O'Brien ... [et al.]. | en_US |
| dc.description | Includes bibliographical references (p. 25-28). | en_US |
| dc.format.extent | 28 p. | en_US |
| dc.identifier.uri | http://hdl.handle.net/11375/16943 | |
| dc.publisher | McMaster University | en_US |
| dc.relation.ispartofseries | CHEPA working paper series no. 96-22 | en_US |
| dc.subject | Cost-Benefit Analysis | en_US |
| dc.subject | Economics, Pharmaceutical | en_US |
| dc.subject | Feasibility Studies | en_US |
| dc.subject | Granulocyte Colony-Stimulating Factor | en_US |
| dc.subject | Managed Care Programs | en_US |
| dc.subject | Neoplasms | en_US |
| dc.subject | drug therapy | en_US |
| dc.subject | Patient Acceptance of Health Care | en_US |
| dc.subject | Relative Value Scales | en_US |
| dc.title | Assessing the value of a new pharmaceutical | en_US |
| dc.type | text | en_US |